[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Practice Gaps
July 2011

Taking Responsibility for Complex Medical Dermatology Patient Management: Comment on “Rituximab for Patients With Refractory Mucous Membrane Pemphigoid ”

Author Affiliations

Author Affiliation: Department of Dermatology, University of Utah, Salt Lake City, Utah.

Arch Dermatol. 2011;147(7):850. doi:10.1001/archdermatol.2011.166

In the article titled “Rituximab for Patients With Refractory Mucous Membrane Pemphigoid ” by Le Roux-Villet et al,1 the authors bring into focus the exceptional value of rituximab in a disease that can cause blindness and extensive mucosal scarring. Therapy for refractory patients in this study is quite remarkable and offers hope to those who have been the victim of severe morbidity and complications from the disease and from the therapy.